TCL Archive Combine Phase 1-2, Abolish DRG, Slash Indirect Costs, Garb Tells Congress November 27, 1981
TCL Archive Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction. April 21, 2006
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Harlow, Abeloff To Chair BSC Subcommittees; Livingston To Head Extramural Advisors September 15, 1995
